Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.
IPO Year: 2020
Exchange: NASDAQ
Website: calliditas.se
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/20/2023 | $60.00 | Buy | H.C. Wainwright |
| 3/1/2023 | $18.00 | Neutral | Guggenheim |
| 12/20/2021 | $52.00 → $62.00 | Buy | HC Wainwright & Co. |
15F-12B - Calliditas Therapeutics AB (0001795579) (Filer)
25-NSE - Calliditas Therapeutics AB (0001795579) (Subject)
SC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)
EFFECT - Calliditas Therapeutics AB (0001795579) (Filer)
SC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)
25 - Calliditas Therapeutics AB (0001795579) (Filer)
S-8 POS - Calliditas Therapeutics AB (0001795579) (Filer)
S-8 POS - Calliditas Therapeutics AB (0001795579) (Filer)
POS AM - Calliditas Therapeutics AB (0001795579) (Filer)
SC 14D9/A - Calliditas Therapeutics AB (0001795579) (Subject)
STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America. Ms Törnsén will be responsible for all US based operations and will report to the CEO. Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles. Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics. Prior to joining Sarepta she serv
FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer. Ms. Henderson will join the Company effective April 5, 2022. Ms. Henderson most recently served as Chief Financial Officer of UroGen Pharma (NASDAQ:URGN), a commercial-stage biopharmaceutical company focused on building novel treatments for specialty cancers and urologic disease. She brings over two decades of global finance expertise and has
Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer
SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)
SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)
SC 13G/A - Calliditas Therapeutics AB (0001795579) (Subject)
SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)
SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)
SC 13D - Calliditas Therapeutics AB (0001795579) (Subject)
SC 13G/A - Calliditas Therapeutics AB (0001795579) (Subject)
SC 13G/A - Calliditas Therapeutics AB (0001795579) (Subject)
SC 13G - Calliditas Therapeutics AB (0001795579) (Subject)
SC 13G - Calliditas Therapeutics AB (0001795579) (Subject)
STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on Thursday, October 10, 2024. For further information, please contact: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email: [email protected] The information was sent for publication, through the agency of the contact person set out above, on September 16, 2024 at 15:30 CET. About Calliditas Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan in
STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the extraordinary general meeting on Monday 30 September 2024 at 12:00 p.m. CEST at Advokatfirman Vinge's premises on Smålandsgatan 20, SE-111 46, Stockholm, Sweden. Registration starts at 11:30 a.m. CEST. Background Asahi Kasei Corporation ("Asahi Kasei"), which has announced that the public offer made regarding the company's shares has been accepted to such extent that Asahi Kasei becomes the owner of more than 90 per cent of the shares and votes in the company, has requested the board of dire
STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the announcement by Asahi Kasei Corporation ("Asahi Kasei") on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (NASDAQ:CALT) ("Calliditas" or the "Company"), and declared its offers to purchase all of the outstanding Common Shares and ADSs of Calliditas unconditional and intends to initiate compulsory redemption of the remaining shares of the Company, the Board of Directors of Calliditas has resolved, in accordance with a request from Asahi Kasei, to take certain corporate actions. Delisting of Common Shares and Delisting, Deregistration, and Termination of ADS Program In light
STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, of which TARPEYO® net sales amounted to SEK 493.4 million, for the three months ended June 30, 2024. For the three months ended June 30, 2023, net sales amounted to SEK 269.4 million, of which TARPEYO net sales amounted to SEK 259.2 million.Operating loss amounted to SEK 31.5 million and SEK 75.2 million for the three months ended June 30, 2024, and 2023, respectively. However, expenses related to the Asahi Kasei offer and expenses related to provisions for social security contribution for incentive prog
STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the second quarter, April - June 2024 will be published in Swedish and English on Tuesday 13 August 2024 at 07.00 a.m. CET. A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén. The presentation will be given in English. Link to the webcast: https://ir.financialhearings.com/calliditas-therapeutics-q2-report-2024 To participate via conference call please register via this link: https://conference.financialhearings.com/tel
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (NASDAQ:CALT) ("Calliditas") Chief Executive Officer, Renée Aguiar-Lucander, will participate in a panel during this year's Women in Nephrology (WIN) Leadership Conference in Los Angeles, CA on August 9 – 10. The panel, titled "How to be Efficient as a Leader in Academia and Industry," will focus on the importance of female representation and leadership. On that topic, Aguiar-Lucander notes, "I believe women in the industry have made great strides in terms of leadership positions but there is clearly still significant work to do. The industry remains male-dominated and closed networks still exist. It's therefore import
STOCKHOLM, July 31, 2024 /PRNewswire/ -- During July, the number of shares and votes in Calliditas Therapeutics AB (publ) has changed due to the exercise of warrants under the company's long-term incentive program issued in 2020, ESOP 2020 and Board of Directors program LTIP 2021. As of today, the total number of outstanding shares in Calliditas Therapeutics AB (publ) amounts to 59,941,465 ordinary shares. The number of votes in Calliditas Therapeutics AB (publ) as of today amounts to 59,941,465. The share capital has increased by SEK 14,455.12 from SEK 2,383,203.48 to SEK 2,397,658.60. For further information, please contact: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46
STOCKHOLM, July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT, Nasdaq Stockholm: CALTX))) ("Calliditas") today announced that the European Commission has granted a full marketing authorization for Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). The European Commission has granted a full marketing authorization of Kinpeygo®. The granting of the full approval results in a significantly broader label for patients with primary IgAN, moving from a urine protein excretion (UPCR) limitation of > 1.5g/g to encompassing the entire study population, defined as UPCR of ≥ 0.8g/g, or proteinuria of ≥1.0 g/g over 24 hours. This expanded label is b
STOCKHOLM, July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (STOCKHOLM: CALTX) ("Calliditas") today announced that the Phase 2b TRANSFORM trial met its primary endpoint, showing statistically significant improvement in ALP (Alkaline Phosphatase) for both doses tested versus placebo. The trial evaluated setanaxib, a NOX enzyme inhibitor, in patients with primary biliary cholangitis (PBC) and elevated liver stiffness. The TRANSFORM trial is a double-blind, randomized, placebo-controlled Phase 2b study investigating the effect of setanaxib 800 mg AM + 400 mg PM, ("1200 mg arm") and 800 mg BID ("1600 mg arm") over 24 weeks of treatment. The basis for the analysis consiste
STOCKHOLM, July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese patients with IgA nephropathy (IgAN). The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in design to that of the global NefIgArd trial. IgA nephropathy is a designated retractable disease in Japan, with an estimated 33,000 patients in Japan* assumed to be suffering from this disease and with limited treatment options for IgAN
H.C. Wainwright initiated coverage of Calliditas Therapeutics AB with a rating of Buy and set a new price target of $60.00
Guggenheim initiated coverage of Calliditas Therapeutics AB with a rating of Neutral and set a new price target of $18.00
HC Wainwright & Co. reiterated coverage of Calliditas Therapeutics with a rating of Buy and set a new price target of $62.00 from $52.00 previously
HC Wainwright initiated coverage of Calliditas Therapeutics AB (publ) with a rating of Buy
H.C. Wainwright initiated coverage of Calliditas Therapeutics AB with a rating of Buy and set a new price target of $52.00
STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, of which TARPEYO® net sales amounted to SEK 493.4 million, for the three months ended June 30, 2024. For the three months ended June 30, 2023, net sales amounted to SEK 269.4 million, of which TARPEYO net sales amounted to SEK 259.2 million.Operating loss amounted to SEK 31.5 million and SEK 75.2 million for the three months ended June 30, 2024, and 2023, respectively. However, expenses related to the Asahi Kasei offer and expenses related to provisions for social security contribution for incentive prog
STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the second quarter, April - June 2024 will be published in Swedish and English on Tuesday 13 August 2024 at 07.00 a.m. CET. A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén. The presentation will be given in English. Link to the webcast: https://ir.financialhearings.com/calliditas-therapeutics-q2-report-2024 To participate via conference call please register via this link: https://conference.financialhearings.com/tel
STOCKHOLM, June 17, 2024 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on 17 June 2024, in Stockholm. Adoption of income statement and balance sheet for the financial year 2023 and discharge from liability The annual general meeting resolved to adopt the income statement and the consolidated income statement for the financial year 2023 as well as the balance sheet and consolidated balance sheet as of 31 December 2023. The members of the Board of Directors and the CEO were discharged from liability for the financial year 2023. Allocation of profit or loss
STOCKHOLM, May 23, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALTX) (STOCKHOLM: CALTX): Target market expansion following full approval in the US JANUARY - MARCH 2024 (COMPARED TO JANUARY - MARCH 2023) Net sales amounted to SEK 295.5 million, of which TARPEYO® net sales amounted to SEK 278.3 million, for the three months ended March 31, 2024. For the three months ended March 31, 2023, net sales amounted to SEK 191.4 million, of which TARPEYO net sales amounted to SEK 185.7 million.Operating loss amounted to SEK 203.8 million and SEK 180.1 million for the three months ended March 31, 2024, and 2023, respectively.Loss per share before and after dilution amounted to SEK 4.59 and
STOCKHOLM, May 16, 2024 /PRNewswire/ -- Calliditas's interim report for the first quarter, January - March 2024 will be published in Swedish and English on Thursday 23 May 2024 at 07.00 a.m. CET. A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén. The presentation will be given in English. Link to the webcast: Calliditas Therapeutics Q1 Report 2024 (financialhearings.com) To participate via conference call please register via this link: https://conference.financialhearings.com/teleconfere
STOCKHOLM, Feb. 21, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX) 2023: Full approval for TARPEYO in the US; a year of successes OCTOBER – DECEMBER 2023(COMPARED TO OCTOBER – DECEMBER 2022) Net sales amounted to SEK 451.6 million, of which TARPEYO® net sales amounted to SEK 347.3 million, for the three months ended December 31, 2023. For the three months ended December 31, 2022, net sales amounted to SEK 429.0 million, of which TARPEYO net sales amounted to SEK 167.3 million.Operating income amounted to SEK 41.8 million and SEK 32.5 million for the three months ended December 31, 2023, and 2022, respectively.Loss per share before and af
STOCKHOLM, Feb. 14, 2024 /PRNewswire/ -- Calliditas' Year-end report for January - December 2023 will be published in Swedish and English on Wednesday 21 February 2024 at 07.00 a.m. CET. A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén. The presentation will be given in English. Link to the webcast: https://ir.financialhearings.com/calliditas-therapeutics-q4-report-2023 To participate via conference call please register via this link: https://conference.financialhearings.com/teleconferen
STOCKHOLM, May 30, 2023 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on 30 May 2023, in Stockholm. Adoption of income statement and balance sheet for the financial year 2022 and discharge from liability The annual general meeting resolved to adopt the income statement and the consolidated income statement for the financial year 2022 as well as the balance sheet and consolidated balance sheet as of 31 December 2022. The members of the Board of Directors and the CEO were discharged from liability for the financial year 2022. Allocation of profit or loss The annual general meeting resolved, in acco
STOCKHOLM, March 13, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon (TARPEYO®/Kinpeygo® (budesonide) delayed release capsules) versus placebo in patients with primary IgA nephropathy (IgAN). The trial met its primary endpoint with Nefecon demonstrating a highly statistically significant benefit over placebo (p value < 0.0001) in estimated glomerular filtration rate (eGFR) over the two-year period of 9-months of treatment with Nefecon or placebo and 15-months of
STOCKHOLM, Dec. 21, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) (NASDAQ:CALT, Nasdaq Stockholm: CALTX))) ("Calliditas") announced today that CEO Renée Aguiar-Lucander has net purchased 50,000 shares through Calliditas' warrant program 2019/2022. Following the new subscription for shares, her shareholding in the company will amount to 643,000 common shares. The majority of the members of management who are eligible option holders in the program have today net purchased shares via the warrant program 2019/2022, which includes 422,500 warrants and can be exercised up to and including December 31, 2022. To partially finance the share purchases, the option holders in the program, inclu